CN Patent

CN115698013B — Menin抑制剂和cyp3a4抑制剂的组合及其使用方法

Assigned to Syndax Pharmaceuticals Inc · Expires 2026-01-02 · 0y expired

What this patent protects

本发明涉及menin抑制剂与一种或多种CYP3A4抑制剂的组合、其药物组合物以及治疗由menin‑MLL相互作用介导的癌症和其他疾病的方法。

USPTO Abstract

本发明涉及menin抑制剂与一种或多种CYP3A4抑制剂的组合、其药物组合物以及治疗由menin‑MLL相互作用介导的癌症和其他疾病的方法。

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: CN115698013B
Jurisdiction: CN
Classification: —
Expires: 2026-01-02
Drug substance claim: No
Drug product claim: No
Assignee: Syndax Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.